- Website value evaluation

immunotope.comWebsite Profile

Title: Website value evaluation
Description:home IMMUNOTOPE is a clinical stage biotechnology company developing immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Our products activate the patient’s is ranked 25408406 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $2,503. This site has a low Pagerank(0/10). It has 1 backlinks. has 43% seo score. Information

Website /
Website IP Address:
Domain DNS,, ranks

Alexa Rank:0
EveryoneDomain Rank:0
Google Page Rank:0/10 (Google Pagerank Has Been Closed) Traffic & Earnings

Purchase/Sale Value:$0
Daily Revenue:$0
Monthly Revenue:$0
Yearly Revenue:$$0
Daily Unique Visitors:0
Monthly Unique Visitors:0
Yearly Unique Visitors:0 WebSite Httpheader

StatusCode 200
Vary Accept-Encoding,User-Agent
Connection Keep-Alive
Cache-Control max-age=-188463536
Content-Type text/html
Server Apache
Date Tue, 25 Sep 2018 10:49:01 GMT WebSite Httpheader

Keyword Count Percentage Alexa Rank History Chart aleax Html To Plain Text

home IMMUNOTOPE is a clinical stage biotechnology company developing immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Our products activate the patient’s own immune system to fight disease and prevent recurrence. Our comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the very earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Our product portfolio includes ovarian, breast, prostate, lung, pancreatic and colon cancer and HBV, HCV, HIV, Influenza and Dengue viral vaccines. Immunotope's platform provides the ideal combination of technologies for successful immunotherapy. We are developing products and services that will: Address the need for highly efficacious, curative treatments with minimal toxicity Use the exquisite sensitivity and specificity of the immune system for early detection of cancer Provide innovative tools and services for collaborative development of novel drug and diagnostic products Provide our shareholders with exceptional returns on their investment We use proprietary immunoproteomics technologies to identify naturally processed and presented antigens associated with Major Histocompatibility Complex Class I and Class II molecules that are present only on diseased cells. Immunotope’s lead product is the IMT-1012 Immunotherapeutic Vaccine, a multivalent cancer therapeutic mixture of twelve different novel antigens, each of which targets a separate, critical pathway known to be present in highly aggressive tumors. After successfully completing a Phase I clinical trial in ovarian and breast cancer patients, Immunotope has licensed 7 antigens from IMT-1012 to Immunovaccine Inc., Halifax, Canada, a vaccine company with DepoVax delivery system. Immunovaccine is conducting a phase I clinical study of DPX-0907 in ovarian, breast and prostate cancer patients. Immunotope has completed pre clinical characterization studies and preparing for phase I clinical study in lung and pancreatic cancer. Immunotope is at the pre clinical stage with therapeutic vaccine development in HCV and HIV and indications and universal prophylactic vaccine development for influenza and dengue virus infections. Immunotope has partnered with Midatech Ltd, UK, a company with gold nanoparticle delivery system and initiated SynTara LLC, a joint venture entity for efficient and complete therapeutic vaccine products commercialization. Immunotope is also applying its platform technology to develop novel autoantibody-based biomarkers for early-stage detection of cancer. Performed as a simple blood test, our products will be rapid, non-invasive and indication-specific early-stage cancer diagnostics. ..................................................................................................................................................................... Clinical and Preclinical Programs | Science & Technology | Careers Business Development | Services | Management and Boards | News and Media | Contact Us | Home ? Copyright Immunotope. All Rights Reserved. Whois

Sponsoring Registrar IANA ID: 69
Whois Server:
Referral URL:
Status: clientDeleteProhibited
Status: clientTransferProhibited
Status: clientUpdateProhibited
Updated Date: 07-apr-2017
Creation Date: 12-dec-2002
Expiration Date: 12-dec-2019
>>> Last update of WHOIS database: 2018-09-25T10:49:01Z

The data contained in, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of, LLC.By submitting an inquiry,
you agree to these terms of usage and limitations of warranty.In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam.You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.

Please note: the registrant of the domain name is specified
in the "registrant" section.In most cases,, LLC
is not the registrant of domain names listed in this database.";

For more information on Whois status codes, please visit